Abstract
The prevalence of diabetes mellitus has prompted significant innovations in drug delivery systems, especially those aimed at achieving tight glycemic control with minimal side effects. Controlled release technologies represent a paradigm shift in the management of diabetes by providing sustained, predictable drug levels over extended periods. Recent advances include microencapsulation, injectable depot systems, glucose-responsive delivery platforms, and smart insulin pumps. These technologies are designed to improve patient compliance, reduce dosing frequency, and mimic physiological insulin secretion more accurately. This paper provides an overview of the current state of controlled release strategies in diabetes therapy, highlighting their mechanisms, benefits, and translational potential.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.